

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Pedro Cuevas Sanchez, et al.  
Application No. : 10/588,166  
Filing Date : February 16, 2005  
Title of Invention : USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN  
THE PRODUCTION OF MEDICAMENTS FOR THE  
TREATMENT OF ANGIODEPENDENT DISEASES SUCH AS  
CANCER AND PSORIASIS  
  
Confirmation No. : 5152  
Examiner : Anna Pagonakis  
Group Art Unit : 1628

**FILED VIA EFS-Web**  
**on January 5, 2011**

745 Fifth Avenue  
New York, NY 10151

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully directed to the following documents set forth in the accompanying form SB/08a. A copy of the cited documents are enclosed.

Applicants request that the Examiner consider and make of record the documents cited herein and that a copy of the form SB/08a, initialed by the Examiner, is returned to Applicants' attorneys. A copy of the Spanish language version of the attached Acnisdin and Acnisdin Retinoico references was previously cited in the Information Disclosure Statement filed on July 27, 2010. We now have English translations available and are submitting them accordingly.

This Information Disclosure Statement is not a representation that the documents cited

herein are considered most pertinent, or that a search has been undertaken, or that the cited documents are indeed prior art. The Examiner is invited to undertake an independent search.

No fee is deemed necessary, since this Information Disclosure Statement is being filed after receipt of the Notice of Allowance mailed October 7, 2010 and is submitted concurrently with Applicants' Request for Continued Examination. If, however a fee is deemed necessary for this submission, the Commissioner is authorized to charge any such required fees to Deposit Account 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By:



Sandra Kuzmich  
Reg. No. 46,117

Kathleen N. Ehrhard  
Reg. No. 55,144

Tel. No. (212) 588-0800  
Fax No. (212) 588-0500